Lamivudine therapy for Japanese patients with cirrhosis B

Intervirology

Volumn 46, Issue 6, 2003, Pages 394-399

  Okanoue, Takeshi ^a   Mori, Kojiro ^a   Kirishima, Toshihiko ^a   Kunimoto, Koji ^a   Yasui, Kohichiroh ^a   Itoh, Yoshito ^a   Minami, Masahito ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis B; Cirrhosis; Lamivudine; Peptide nucleic acid; YMDD mutants

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; LAMIVUDINE;

ADULT; BLOOD SAMPLING; COMPARATIVE STUDY; CONFERENCE PAPER; ENZYME ASSAY; ENZYME BLOOD LEVEL; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONITOR; MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS MUTATION;

CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; FIBROSIS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; JAPAN; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0346786524     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074998     Document Type: Conference Paper

References (23)

1. Hoofnagle JH: Type B hepatitis: Virology, serology and clinical course. Semin Liver Dis 1981;1:7-14.
2. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC: Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′- thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-8499.
3. Chang CN, Skalski V, Zhou JH, Cheng YC: Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992;267:22414-22420.
4. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
5. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
6. Dienstag JL, Schiff ER, Mitchell M, Casey DE Jr, Gitlin N, Lissoos T, Gelb LD, Condreay L, Crowther L, Rubin M, Brown N: Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy. Hepatology 1999;30:1082-1087.
7. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER: Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-117.
8. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF: A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68.
9. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-180.
10. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ: Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-713.
11. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL: Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-717.
12. Schalm SW: Clinical implications of lamivudine resistance by HBV. Lancet 1997;349:3-4.
13. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW: Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997;26:1393-1395.
14. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-1677.
15. Fischer KP, Gutfreund KS, Tyrrell DL: Lamivudine resistance in hepatitis B: Mechanisms and clinical implications. Drug Resist Updat 2001;4:118-128.
16. Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, Toyama T, Minami M: Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002;37:259-265.
17. Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-1716.
18. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572.
19. Paik YH, Chung HY, Ryu WS, Lee KS, Lee JS, Kim JH, Lee CK, Chon CY, Moon YM, Han KH: Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea. J Hepatol 2001;35:92-98.
20. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-1532.
21. Kobayashi S, Ide T, Sata M: Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001;34:584-586.
22. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-791.
23. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH: Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-834.